madrigalpharma.com
Contact us
About company
Madrigal is pursuing a novel NASH treatment, resmetirom, that has the potential to become the first therapy for non-alcoholic steatohepatitis with liver fibrosis.
US 200 barr harbor drive
Unknown
Not verified company
